Advaxis (ADXS) Trading Down 0%

Advaxis, Inc. (NASDAQ:ADXS) shares fell 0% on Monday . The stock traded as low as $2.92 and last traded at $2.98. 1,187,409 shares were traded during trading, an increase of 26% from the average session volume of 942,074 shares. The stock had previously closed at $2.98.

Several brokerages have recently weighed in on ADXS. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of Advaxis in a research note on Friday, September 15th. Cantor Fitzgerald reiterated a “buy” rating and set a $19.00 price target on shares of Advaxis in a research note on Monday, September 25th. Finally, ValuEngine cut shares of Advaxis from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 3rd.

The stock has a market cap of $117.45, a P/E ratio of -1.26 and a beta of 1.91.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.02). The business had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $3.05 million. Advaxis had a negative return on equity of 114.00% and a negative net margin of 776.63%. sell-side analysts forecast that Advaxis, Inc. will post -2.36 earnings per share for the current year.

In related news, insider Robert Petit sold 12,625 shares of Advaxis stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,273.75. Following the transaction, the insider now owns 237,265 shares in the company, valued at approximately $756,875.35. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Sara Bonstein sold 12,734 shares of Advaxis stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,621.46. Following the transaction, the chief financial officer now owns 244,504 shares in the company, valued at approximately $779,967.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,192 shares of company stock worth $122,615. 7.21% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADXS. Voya Investment Management LLC lifted its stake in shares of Advaxis by 20.3% during the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 2,975 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Advaxis by 18.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 4,000 shares in the last quarter. Stonebridge Capital Management Inc. lifted its stake in shares of Advaxis by 88.7% during the 3rd quarter. Stonebridge Capital Management Inc. now owns 42,650 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 20,045 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Advaxis during the 2nd quarter valued at $201,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Advaxis by 10.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 2,969 shares in the last quarter. Institutional investors own 41.65% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.themarketsdaily.com/2018/01/10/advaxis-adxs-trading-down-0.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply